Korean J Urol.  2010 Jan;51(1):64-69.

Urodynamic Effects of Propiverine on Detrusor Overactivity and Abdominal Straining during Voiding in Awake Rats with Intravesical Prostaglandin E2 Instillation

• Oh JH
• Lee YS
• Jin LH
• Kwon YH
• Park WH
• Lee T

Abstract

PURPOSE
We investigated the effect of propiverine on cystometric parameters based on intraabdominal pressure (IAP) in awake rats in an overactive bladder (OAB) model induced by intravesical instillation of prostaglandin E2 (PGE2). MATERIALS AND METHODS: Twenty-two female Sprague-Dawley rats were used. Polyethylene catheters were implanted into the bladder to record the intravesical pressure (IVP) and into the femoral artery to administer medication. A balloon-fitted catheter was positioned in the abdominal cavity to record the IAP. Awake cystometries were performed before and after intraarterial administration of propiverine 1 mg/kg (n=6), intravesical administration of 50microM PGE2 only (n=6), or intravesical PGE2 plus 1 mg/kg (n=4) or 3 mg/kg (n=6) of intraarterial propiverine. Cystometric pressure and volume parameters and variables related to detrusor overactivity (DO) were investigated. RESULTS: Rats administered intravesical PGE2 showed increased pressure parameters and decreased volume parameters comparable to the DO model, which was effectively prevented by propiverine (1 or 3 mg/kg). Typical DO shown during the filling phase was decreased by intraarterial propiverine (3 mg/kg) injection. After propiverine (3 mg/kg) injection, IAP was increased at the time of micturition pressure with or without threshold pressure (p<0.05, p<0.01) depending on the dose administered. CONCLUSIONS: Propiverine improved pressure- and volume-related parameters in an OAB model. Furthermore, it also decreased the frequency of DO. However, higher concentrations of propiverine induced straining voiding.

Keyword

Propiverine; Sprague-Dawley rats; Prostaglandins

MeSH Terms

Abdominal Cavity
Administration, Intravesical
Animals
Benzilates
Catheters
Dinoprostone
Female
Femoral Artery
Humans
Polyethylene
Prostaglandins
Rats
Rats, Sprague-Dawley
Sprains and Strains
Urinary Bladder
Urinary Bladder, Overactive
Urination
Urodynamics
Benzilates
Dinoprostone
Polyethylene
Prostaglandins

Reference

1. Hu TW, Wagner TH. Economic considerations in overactive bladder. Am J Manag Care. 2000. 6:11 Suppl. S591–S598.

2. Grocela JA, Kanji A, Ternullo J. Prediction of medicare drug formulary drugs for treatment of overactive bladder. J Urol. 2006. 176:252–255.

3. Dmochowski RR. The puzzle of overactive bladder: controversies, inconsistencies, and insights. Int Urogynecol J Pelvic Floor Dysfunct. 2006. 17:650–658.

4. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002. 21:167–178.

5. Hashim H, Abrams P. Drug treatment of overactive bladder: efficacy, cost and quality-of-life considerations. Drugs. 2004. 64:1643–1656.

6. Hyman MJ, Groutz A, Blaivas JG. Detrusor instability in men: correlation of lower urinary tract symptoms with urodynamic findings. J Urol. 2001. 166:550–552.

7. Digesu GA, Khullar V, Cardozo L, Salvatore S. Overactive bladder symptoms: do we need urodynamics? Neurourol Urodyn. 2003. 22:105–108.

8. Jin LH, Andersson KE, Kwon YH, Park CS, Yoon SM, Lee T. Substantial detrusor overactivity in conscious spontaneously hypertensive rats with hyperactive behaviour. Scand J Urol Nephrol. 2009. 43:3–7.

9. Alberts P. Classification of the presynaptic muscarinic receptor subtype that regulates 3H-acetylcholine secretion in the guinea pig urinary bladder in vitro. J Pharmacol Exp Ther. 1995. 274:458–468.

10. Andersson KE. Changes in bladder tone during filling: pharmacological aspects. Scand J Urol Nephrol Suppl. 1999. 201:67–72.

11. Stöhrer M, Mürtz G, Kramer G, Schnabel F, Arnold EP, Wyndaele JJ. Propiverine compared to oxybutynin in neurogenic detrusor overactivity--results of a randomized, double-blind, multicenter clinical study. Eur Urol. 2007. 51:235–242.

12. Lee T, Andersson KE, Streng T, Hedlund P. Simultaneous registration of intraabdominal and intravesical pressures during cystometry in conscious rats--effects of bladder outlet obstruction and intravesical PGE2. Neurourol Urodyn. 2008. 27:88–95.

13. Andersson KE. Antimuscarinics for treatment of overactive bladder. Lancet Neurol. 2004. 3:46–53.

14. Andersson KE. Overactive bladder--pharmacological aspects. Scand J Urol Nephrol Suppl. 2002. 210:72–81.

15. Schörder A, Newgreen D, Andersson KE. Detrusor responses to prostaglandin E2 and bladder outlet obstruction in wild-type and Ep1 receptor knockout mice. J Urol. 2004. 172:1166–1170.

16. Wheeler MA, Hausladen DA, Yoon JH, Weiss RM. Prostaglandin E2 production and cyclooxygenase-2 induction in human urinary tract infections and bladder cancer. J Urol. 2002. 168:1568–1573.

17. Palea S, Toson G, Pietra C, Trist DG, Artibani W, Romano O, et al. Pharmacological characterization of thromboxane and prostanoid receptors in human isolated urinary bladder. Br J Pharmacol. 1998. 124:865–872.

18. Andersson KE, Wein AJ. Pharmacology of the lower urinary tract: basis for current and future treatments of urinary incontinence. Pharmacol Rev. 2004. 56:581–631.

19. Atan A, Konety BR, Erickson JR, Yokoyama T, Kim DY, Chancellor MB. Tolterodine for overactive bladder: time to onset of action, preferred dosage, and 9-month follow-up. Tech Urol. 1999. 5:67–70.

20. Brynne N, Stahl MM, Hallen B, Edlund PO, Palmer L, Höglund P, et al. Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity. Int J Clin Pharmacol Ther. 1997. 35:287–295.

21. Martin-Merino E, Garcia-Rodriguez LA, Masso-Gonzalez EL, Roehrborn CG. Do oral antimuscarinic drugs carry an increased risk of acute urinary retention? J Urol. 2009. 182:1442–1448.